Koka Kirthi, Mukherjee Bipasha, Agarkar Sumita
Orbit, Oculoplasty, Reconstructive & Aesthetic Services, Sankara Nethralaya, Medical Research Foundation, Chennai, India.
Orbit, Oculoplasty, Reconstructive & Aesthetic Services, Sankara Nethralaya, Medical Research Foundation, Chennai, India.
Pediatr Neonatol. 2018 Aug;59(4):390-396. doi: 10.1016/j.pedneo.2017.11.021. Epub 2017 Dec 6.
To assess the safety and efficacy of oral propranolol in the management of periocular Capillary Hemangiomas of Infancy (CHI).
Medical records of 21 infants diagnosed with periocular capillary hemangioma during a period of 5 years from 2009 to 2014 were retrospectively reviewed. The data collected included demographic details, clinical features and details of imaging studies and response to the therapy. All patients received oral propranolol under the supervision of a pediatrician. The initial dose was 0.2-1 mg/kg body weight, which was increased to 2 mg/kg body weight (3 divided doses) in 48 h if there was no adverse reaction to the initial dose. The response to the treatment was assessed clinically as well as by radiographic imaging. Photographic documentation was done periodically.
Out of 21 patients, 18 were females and remaining three were males. The median age at the time of presentation was 4 months. The most common presenting feature was lid mass (n = 17, 80%) followed by proptosis (n = 7, 33%). Reddish discoloration of face was seen in 2 (1%) patients. All patients showed reduction in the size of the lesion. None of the patients included in this study had any adverse reaction to propranolol or recurrence following cessation of the therapy.
Oral propranolol is highly effective and safe in the treatment of periocular capillary hemangiomas in infants.
评估口服普萘洛尔治疗婴儿眼眶周围毛细血管瘤（CHI）的安全性和有效性。
回顾性分析2009年至2014年5年间21例诊断为眼眶周围毛细血管瘤婴儿的病历。收集的数据包括人口统计学细节、临床特征、影像学研究细节及治疗反应。所有患者均在儿科医生的监督下口服普萘洛尔。初始剂量为0.2 - 1毫克/千克体重，若对初始剂量无不良反应，则在48小时内将剂量增至2毫克/千克体重（分3次服用）。通过临床及影像学检查评估治疗反应，并定期进行照片记录。
21例患者中，18例为女性，其余3例为男性。就诊时的中位年龄为4个月。最常见的表现为眼睑肿物（n = 17，80%），其次为眼球突出（n = 7，33%）。2例（1%）患者面部有红色色素沉着。所有患者病变大小均减小。本研究中所有患者对普萘洛尔均无不良反应，治疗停止后也无复发。
口服普萘洛尔治疗婴儿眼眶周围毛细血管瘤高效且安全。
